Company · Healthtech & Bio

Anaconda Biomed

anaconda.bio ↗ ·Sant Cugat del Vallès ·Series B

Anaconda Biomed is a Barcelona-based (Sant Cugat del Vallès) clinical-stage neurovascular medical device company developing next-generation endovascular access and protection technology to treat acute ischemic stroke caused by large vessel occlusion. Its flagship product, the ANA5 Funnel Catheter, is a self-expanding aspiration thrombectomy device that has received CE Mark and is investigational in the U.S. The company has raised roughly $39-50M across Series A and Series B rounds from European and US life-science investors.

Founded

2015

Founders

News

Rounds

Investors

SectorsMedical Devices, Neurovascular, Stroke Care, Healthtech Start-up MapHealthtech & Bio › Medical devices & surgical hardware

Profile updated 28 Jul 2026

Founders

Marc Ribó

Co-Founder (Scientific Advisory Board)

Ofir Arad

Co-Founder & Managing Director

Global models 5

Imperative Care

United States · www.imperativecare.com ↗

US neurovascular/thrombectomy platform company developing stroke and venous thromboembolism devices, the largest VC-backed pure-play comparable to Anaconda's stroke thrombectomy focus.

$663MComparable

Route 92 Medical

United States · www.route92medical.com ↗

VC-backed developer of aspiration-based mechanical thrombectomy systems for acute ischemic stroke, directly comparable to Anaconda's ANA5 catheter.

$270M+Comparable

Endovascular Engineering

United States · www.endovasceng.com ↗

Venture-backed maker of mechanical thrombectomy platforms for peripheral and neurovascular clot removal, same aspiration-thrombectomy device category.

$137MComparable

Rapid Medical

Israel · www.rapid-medical.com ↗

VC-funded neurovascular device maker building stent-retriever and thrombectomy tools for stroke treatment, a close device-category peer.

$80MComparable

Neuravi

Ireland · www.neuravi.com ↗

VC-backed Irish neurovascular thrombectomy device developer acquired by J&J's Cerenovus, matching Anaconda's stroke-device model and eventual strategic-exit path.

$44.5MComparable